ERCC1 and non-small cell lung carcinoma: In a previous meta-analysis, it was found that sensitivity to chemotherapy with platinum drugs among patients without ERCC1 expression in the middle and late stages of NSCLC was better than in patients with positive expression (p < 0.01) [32].